Provid has generated a pipeline of proprietary product candidates through internal research and development. This include compounds targeting autoimmune diseases, oncology, cardiovascular and infectious diseases.
Provid's internal drug discovery pipeline includes PV-267, our MHC class II DR2 inhibitor for the treatment of multiple sclerosis. This work is being funded in part by Fast Forward, LLC, the venture philanthropy arm of the National Multiple Sclerosis Society. The platform technology of MHC class II inhibition has generated projects and lead compounds that target other autoimmune diseases. These are directed toward the MHC alleles for DR1- and DR4-associated diseases (e.g., rheumatoid arthritis) as well as DQ alleles associated with celiac disease and type 1 diabetes.
In oncology, Provid has discovered PV-1019, a potent, highly selective inhibitor of Chk2 kinase, a target of importance for oncology. This work was done in collaboration with the NCI. PV-1019 kills tumor cells that are dependent on Chk2, synergizes with DNA-damaging chemotherapeutic agents, and protects normal cells from DNA damage by radiation and chemotherapeutic agents.
Other early stage programs target RNA polymerase for infectious disease and F11R for atherosclerosis. Both are grant-funded projects with academic groups (Rutgers, SUNY Downstate).
